Table 3.
Summary of published studies on vaccination studies, antigens used, and their obtained efficacy.
| Reference | Antigen | Vaccine type | Vaccine efficacy |
|---|---|---|---|
| Smith et al. (35) | Killed bacterin | Formalin inactivated | Inconsistent results |
| Kuzyk et al. (37) | OspA (outer surface protein A) | Recombinant subunit vaccine + T cell epitopes | 83% RPS |
| Miquel et al. (48) | Whole genome | DNA (gene expression library) | Mortality 80% (inconsistent results) |
| Birkbeck et al. (36) | Inactivated bacterin (Scottish isolate SCO-95A) | Heat- or formalin-inactivated | 70.7% RPS |
| 49.6% RPS | |||
| Wilhelm et al. (76) | Hsp60 Hsp70 | Recombinant subunit vaccine | 8% mortality |
| Salonius et al. (47) – Commercial vaccine against BKD (Canada) | Arthrobacter davidanieli | Live vaccine | Laboratory results 2% mortality. Field results 6.7% mortality |
| Wilhelm et al. (39) | (V1) Hsp60/70 + FlgG | Recombinant vaccine including Freund’s adjuvant | (V1) 95–94.5% RPS |
| (V2) TbpB + MltB | (V2) 85% | ||
| (V3) Omp27 + FlaA | (V3) 10.4% | ||
| Tobar et al. (56) | Inactivated bacterin, P. salmonis strain PS2C | Inactivated, whole bacterial antigen formulated in micromatrix for oral delivery or i.p. injection (or combined) | Onset of immunity by 300 degree days (oral group). IP boosted with oral (1500 degree days), good protection by 1800 degree days post primary immunization (300 degree days post boost) |